{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:03:03Z","timestamp":1790758983864,"version":"4.1.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031031","name":"University Children's Hospital Basel UKBB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031031","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\u201cYoung Talents in Clinical Research\u201d"},{"DOI":"10.13039\/501100015508","name":"SAMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015508","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020137","name":"G. & J. Bangerter-Rhyner Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020083","name":"Research Council of the Kantonsspital Aarau","doi-asserted-by":"publisher","award":["1410.000.172"],"award-info":[{"award-number":["1410.000.172"]}],"id":[{"id":"10.13039\/501100020083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016071","name":"Margot und Erich Goldschmidt & Peter Ren\u00e9 Jacobson-Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rare bone diseases comprise a heterogeneous group of complex and disabling conditions. Evidence on age-specific hospitalization patterns and in-hospital outcomes across multiple rare bone diseases is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Population-based cohort study using national hospitalization data (01\/2012-12\/2021). Among 11 092 151 hospitalizations, 2875 admissions of children and adults with rare bone diseases were identified via ICD-10 codes (X-linked hypophosphatemia, osteogenesis imperfecta, fibrous dysplasia, achondroplasia, pseudohypoparathyroidism, fibrodysplasia ossificans progressiva) and compared with 14 375 age-, sex-, and patient complexity\u2013matched hospitalizations from the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Hospitalization patterns differed substantially by disease and age. Patients with X-linked hypophosphatemia had an increased risk of emergency admissions in late adulthood, whereas planned admissions were more frequent in early adulthood among patients with achondroplasia and fibrous dysplasia. Malignancies were diagnosed in 22.7% of patients with X-linked hypophosphatemia, and fractures were the leading cause of hospitalization among patients with osteogenesis imperfecta. Across the rare bone diseases, patients had higher all-cause in-hospital mortality compared with matched controls (RR, 2.26; 95% CI, 1.77-2.89), longer hospital stays (median difference, 6 days [interquartile range [IQR] 3-13 days]), higher risk of ICU admission (RR, 3.08; 95% CI, 2.78-3.40), and higher readmission risk (RR, 1.31, 95% CI, 1.15-1.49).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The studied rare bone diseases are associated with distinct, disease-specific hospitalization patterns and substantially worse in-hospital outcomes across the lifespan. This underscores the need for tailored preventive strategies and coordinated, long-term care models for patients with rare bone diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag171","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:50:03Z","timestamp":1788432603000},"page":"518-528","source":"Crossref","is-referenced-by-count":0,"title":["Adverse health outcomes across the life course in individuals with six rare bone diseases: a 10-year population-based cohort study"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-8913","authenticated-orcid":false,"given":"Pascal","family":"Gaechter","sequence":"first","affiliation":[{"name":"Pediatric Endocrinology and Diabetology, University Children's Hospital Basel UKBB, University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4001 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0619-821X","authenticated-orcid":false,"given":"Christian","family":"Meier","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Basel , Basel 4001 ,","place":["Switzerland"]},{"name":"Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-4606","authenticated-orcid":false,"given":"Emanuel","family":"Christ","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Basel , Basel 4001 ,","place":["Switzerland"]},{"name":"Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5862-966X","authenticated-orcid":false,"given":"Fahim","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4001 ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Basel , Basel 4001 ,","place":["Switzerland"]},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institute , Stockholm 17177 ,","place":["Sweden"]},{"name":"Department of Gastroenterology & Hepatology, University Digestive Health Care Center Basel\u2014Clarunis , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-5648","authenticated-orcid":false,"given":"Alexander","family":"Kutz","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4001 ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Basel , Basel 4001 ,","place":["Switzerland"]},{"name":"Division of General Internal and Primary Care Medicine, University Department of Medicine, Kantonsspital Aarau , Aarau 5001 ,","place":["Switzerland"]},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0559-2597","authenticated-orcid":false,"given":"Gabor","family":"Szinnai","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology and Diabetology, University Children's Hospital Basel UKBB, University of Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University Hospital Basel, University of Basel , Basel 4001 ,","place":["Switzerland"]},{"name":"Medical Faculty, University of Basel , Basel 4001 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"5","key":"2026093004251087800_lvag171-B1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ajmg.a.63132","article-title":"Nosology of genetic skeletal disorders: 2023 revision","volume":"191","author":"Unger","year":"2023","journal-title":"Am J Med Genet A"},{"issue":"8","key":"2026093004251087800_lvag171-B2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00198-023-06791-x","article-title":"Improving care pathways for people living with rare bone diseases (RBDs): outcomes from the first RBD Summit","volume":"34","author":"Chandran","year":"2023","journal-title":"Osteoporos Int"},{"issue":"5","key":"2026093004251087800_lvag171-B3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"21","author":"Haffner","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2026093004251087800_lvag171-B4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2026093004251087800_lvag171-B5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41574-024-01074-9","article-title":"International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia","volume":"21","author":"Savarirayan","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026093004251087800_lvag171-B6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13023-024-03345-0","article-title":"Osteogenesis Imperfecta: a study of the patient journey in 13 European countries","volume":"19","author":"Westerheim","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026093004251087800_lvag171-B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13023-023-02652-2","article-title":"Lifetime Impact of Achondroplasia Study in Europe (LIAISE): findings from a multinational observational study","volume":"18","author":"Maghnie","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026093004251087800_lvag171-B8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13023-023-02811-5","article-title":"Higher rates of non-skeletal complications and greater healthcare needs in achondroplasia compared to the general UK population: a matched cohort study using the CPRD database","volume":"18","author":"Pimenta","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026093004251087800_lvag171-B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jbmr.2920","article-title":"Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study","volume":"32","author":"Folkestad","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2026093004251087800_lvag171-B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.869604","article-title":"Prevalence and hospital admissions in patients with osteogenesis imperfecta in the Netherlands: a nationwide registry study","volume":"13","author":"Storoni","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"2026093004251087800_lvag171-B11","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf124","article-title":"Real-world data of fracture rates and musculoskeletal disorders for patients living with osteogenesis imperfecta","volume":"9","author":"Yang","year":"2025","journal-title":"JBMR Plus"},{"issue":"1","key":"2026093004251087800_lvag171-B12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","article-title":"The international X-linked hypophosphatemia (XLH) registry: first interim analysis of baseline demographic, genetic and clinical data","volume":"18","author":"Ariceta","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026093004251087800_lvag171-B13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11657-025-01544-1","article-title":"Real-world characteristics & disease history of patients with X-linked hypophosphatemia before treatment with burosumab","volume":"20","author":"Dahir","year":"2025","journal-title":"Arch Osteoporos"},{"issue":"12","key":"2026093004251087800_lvag171-B14","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1002\/jbmr.2894","article-title":"Prognostic factors from an epidemiologic evaluation of fibrous dysplasia of bone in a modern cohort: the FRANCEDYS study","volume":"31","author":"Benhamou","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026093004251087800_lvag171-B15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13023-024-03102-3","article-title":"The health-care utilization and economic burden in patients with genetic skeletal disorders","volume":"19","author":"Liu","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"2026093004251087800_lvag171-B16"},{"key":"2026093004251087800_lvag171-B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2024.104916","article-title":"ERN BOND: the key European network leveraging diagnosis, research, and treatment for rare bone conditions","volume":"68","author":"Casareto","year":"2024","journal-title":"Eur J Med Genet"},{"issue":"12","key":"2026093004251087800_lvag171-B18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"3","key":"2026093004251087800_lvag171-B19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/joim.13497","article-title":"Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: a nationwide population-based cohort study","volume":"292","author":"Wester","year":"2022","journal-title":"J Intern Med"},{"key":"2026093004251087800_lvag171-B20","article-title":"Epidemiology of imperfect osteogenesis: a rare disease in the valencia region","volume":"91","author":"Gimeno-Martos","year":"2017","journal-title":"Rev Esp Salud Publica"},{"issue":"4","key":"2026093004251087800_lvag171-B21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1399-0004.1989.tb03198.x","article-title":"Osteogenesis imperfecta: a genetic, radiological, and epidemiological study","volume":"36","author":"Andersen","year":"1989","journal-title":"Clin Genet"},{"issue":"6","key":"2026093004251087800_lvag171-B22","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1210\/clinem\/dgad744","article-title":"Incidence and prevalence of fibrous Dysplasia\/McCune-Albright syndrome: a nationwide registry-based study in Denmark","volume":"109","author":"Meier","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2026093004251087800_lvag171-B23","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1002\/ajmg.a.32485","article-title":"The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US","volume":"146a","author":"Waller","year":"2008","journal-title":"Am J Med Genet A"},{"issue":"8","key":"2026093004251087800_lvag171-B24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41574-018-0042-0","article-title":"Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement","volume":"14","author":"Mantovani","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026093004251087800_lvag171-B25","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-80","article-title":"Fibrodysplasia ossificans progressiva: clinical and genetic aspects","volume":"6","author":"Pignolo","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2026093004251087800_lvag171-B26","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00198-020-05755-9","article-title":"Hospital admissions of patients with osteogenesis imperfecta in the English NHS","volume":"32","author":"Kolovos","year":"2021","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026093004251087800_lvag171-B27","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/13696998.2020.1834402","article-title":"Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis","volume":"23","author":"Darb\u00e0","year":"2020","journal-title":"J Med Econ"},{"issue":"4","key":"2026093004251087800_lvag171-B28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1359\/JBMR.0301262","article-title":"Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome","volume":"19","author":"Leet","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026093004251087800_lvag171-B29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2106\/00004623-198769030-00012","article-title":"Fibrous dysplasia. An analysis of options for treatment","volume":"69","author":"Stephenson","year":"1987","journal-title":"J Bone Joint Surg Am"},{"issue":"15","key":"2026093004251087800_lvag171-B30","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2217\/cer-2021-0250","article-title":"National burden of achondroplasia: an analysis of the national inpatient and nationwide ambulatory surgery samples","volume":"11","author":"Broder","year":"2022","journal-title":"J Comp Eff Res"},{"issue":"4","key":"2026093004251087800_lvag171-B31","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/ajmg.a.62096","article-title":"CLARITY: co-occurrences in achondroplasia-craniosynostosis, seizures, and decreased risk of diabetes mellitus","volume":"185","author":"Legare","year":"2021","journal-title":"Am J Med Genet A"},{"issue":"1","key":"2026093004251087800_lvag171-B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/archdischild-2025-328595","article-title":"Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review","volume":"111","author":"Buciek","year":"2026","journal-title":"Arch Dis Child"},{"issue":"1","key":"2026093004251087800_lvag171-B33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13023-021-01792-7","article-title":"Obstructive sleep apnea in Norwegian adults with achondroplasia: a population-based study","volume":"16","author":"Fredwall","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2026093004251087800_lvag171-B34","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1210\/jc.2016-2215","article-title":"Fibroblast growth factor 23 and cause-specific mortality in the general population: the Northern Manhattan Study","volume":"101","author":"Souma","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026093004251087800_lvag171-B35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ejendo\/lvae089","article-title":"Metabolically healthy obesity in adults with X-linked hypophosphatemia","volume":"191","author":"Lecoq","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026093004251087800_lvag171-B36","doi-asserted-by":"publisher","first-page":"e971","DOI":"10.1210\/clinem\/dgad246","article-title":"Fibroblast growth factor 23, glucose homeostasis, and incident diabetes: findings of 2 cohort studies","volume":"108","author":"van der Vaart","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2026093004251087800_lvag171-B37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1056\/NEJM198011273032203","article-title":"Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin","volume":"303","author":"DeFronzo","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"2026093004251087800_lvag171-B38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/ATVBAHA.110.214619","article-title":"Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals","volume":"31","author":"Mirza","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2026093004251087800_lvag171-B39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1530\/EC-19-0481","article-title":"Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia","volume":"9","author":"Zhukouskaya","year":"2020","journal-title":"Endocr Connect"},{"issue":"2","key":"2026093004251087800_lvag171-B40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1210\/clinem\/dgad524","article-title":"Clinical and molecular characteristics and long-term follow-up of children with pseudohypoparathyroidism type IA","volume":"109","author":"Ludar","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026093004251087800_lvag171-B41","doi-asserted-by":"publisher","first-page":"E1796","DOI":"10.1210\/jc.2013-1594","article-title":"Reduced insulin sensitivity in adults with pseudohypoparathyroidism type 1a","volume":"98","author":"Muniyappa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026093004251087800_lvag171-B42","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1210\/jc.2018-01067","article-title":"Glucose homeostasis and energy balance in children with pseudohypoparathyroidism","volume":"103","author":"Perez","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026093004251087800_lvag171-B43","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026093004251087800_lvag171-B44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1229750","article-title":"Elevated morbidity and mortality in patients with chronic idiopathic hypophosphatemia: a nationwide cohort study","volume":"14","author":"Kim","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026093004251087800_lvag171-B45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1210\/er.2017-00220","article-title":"X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment","volume":"39","author":"Kinoshita","year":"2018","journal-title":"Endocr Rev"},{"issue":"8","key":"2026093004251087800_lvag171-B46","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026093004251087800_lvag171-B47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026093004251087800_lvag171-B48","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/ajmg.a.40528","article-title":"Multicenter study of mortality in achondroplasia","volume":"176","author":"Hashmi","year":"2018","journal-title":"Am J Med Genet A"},{"issue":"21","key":"2026093004251087800_lvag171-B49","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1002\/ajmg.a.31919","article-title":"Mortality in achondroplasia study: a 42-year follow-up","volume":"143a","author":"Wynn","year":"2007","journal-title":"Am J Med Genet A"},{"issue":"4","key":"2026093004251087800_lvag171-B50","first-page":"1","article-title":"Switzerland: health system review","volume":"17","author":"De Pietro","year":"2015","journal-title":"Health Syst Transit"},{"issue":"6","key":"2026093004251087800_lvag171-B51","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/cen.12948","article-title":"Pseudohypoparathyroidism\u2014epidemiology, mortality and risk of complications","volume":"84","author":"Underbjerg","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026093004251087800_lvag171-B52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13023-025-03763-8","article-title":"Understanding the clinical morbidity and mortality of fibrodysplasia ossificans progressiva: a systematic literature review","volume":"20","author":"Harrak","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2026093004251087800_lvag171-B53","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/jbmr.2895","article-title":"Mortality and causes of death in patients with osteogenesis Imperfecta: a register-based nationwide cohort study","volume":"31","author":"Folkestad","year":"2016","journal-title":"J Bone Miner Res"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag171\/70937977\/lvag171.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/3\/518\/70937977\/lvag171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/3\/518\/70937977\/lvag171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:25:56Z","timestamp":1790756756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/3\/518\/8781000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag171","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,28]]}}}